No single ticker was named. Biotech ETFs are one way for retail investors to get exposure. Not a recommendation.
Alexandria Real Estate poised for long-term recovery
The bull case for Alexandria Real Estate Equities is that its stock has been excessively penalized by temporary biotech oversupply, leaving it trading at a steep discount to its liquidation value.
The argument
The guest argued that despite a dividend cut and lowered guidance due to a prolonged oversupply of lab space, the company's underlying real estate portfolio is estimated by analysts to have a liquidation value of $110 per share, compared to a trading price in the $40s.
The thesis, stress-tested
✓ What validates it
- ✓Successful execution of non-income-producing asset sales to shore up the balance sheet
- ✓Stabilization of rental rates and occupancy levels in key biotech clusters
▸ Risks discussed
- ▸Prolonged oversupply in the lab and office markets
- ▸Changes in NIH funding or federal drug spending policies dampening biotech expansion
Hear it yourself
"And so that's so analysts, they say, almost all of them to a t say that the the liquidation value of this real estate portfolio would be about a 110, you know, after all the debt and everything, but the stock's at 47."
00:00 / 00:15